Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) — Tangible Net Worth Ratio
Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) has a Tangible Net Worth Ratio of 90.9% as of March 2026. This metric is calculated by deducting intangible assets (CN¥171.37 Million) from net assets (CN¥1.89 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See 002940 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Zhejiang Anglikang Pharmaceutical Co Ltd Class A Tangible Net Worth Ratio (2014–2025)
This chart shows how Zhejiang Anglikang Pharmaceutical Co Ltd Class A's Tangible Net Worth Ratio has changed across 12 annual periods from 2014 to 2025. As of March 2026, the ratio stands at 90.9%, reflecting net assets of CN¥1.89 Billion with intangible assets of CN¥171.37 Million CNY. See Zhejiang Anglikang Pharmaceutical Co Ltd (002940) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Zhejiang Anglikang Pharmaceutical Co Ltd Class A (2014–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Zhejiang Anglikang Pharmaceutical Co Ltd Class A from 2014 to 2025, covering 12 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see market value of Zhejiang Anglikang Pharmaceutical Co Ltd.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 90.7% | CN¥1.87 Billion | CN¥173.68 Million | CN¥2.95 Billion | ▲ +0.6 pp |
| 2024 | 90.1% | CN¥1.80 Billion | CN¥178.73 Million | CN¥2.97 Billion | ▼ -0.8 pp |
| 2023 | 90.8% | CN¥1.83 Billion | CN¥168.14 Million | CN¥3.02 Billion | ▼ -6.8 pp |
| 2022 | 97.6% | CN¥1.65 Billion | CN¥38.78 Million | CN¥2.60 Billion | ▲ +0.4 pp |
| 2021 | 97.3% | CN¥1.47 Billion | CN¥40.05 Million | CN¥2.08 Billion | ▼ 0.0 pp |
| 2020 | 97.3% | CN¥1.38 Billion | CN¥36.88 Million | CN¥1.94 Billion | ▲ +1.1 pp |
| 2019 | 96.2% | CN¥1.02 Billion | CN¥38.87 Million | CN¥1.38 Billion | ▲ +0.3 pp |
| 2018 | 95.9% | CN¥970.93 Million | CN¥40.15 Million | CN¥1.47 Billion | ▲ +6.5 pp |
| 2017 | 89.4% | CN¥394.37 Million | CN¥41.89 Million | CN¥906.78 Million | ▲ +2.7 pp |
| 2016 | 86.6% | CN¥327.43 Million | CN¥43.75 Million | CN¥727.99 Million | ▲ +3.9 pp |
| 2015 | 82.7% | CN¥264.20 Million | CN¥45.68 Million | CN¥799.83 Million | ▲ +5.2 pp |
| 2014 | 77.5% | CN¥217.08 Million | CN¥48.82 Million | CN¥731.44 Million | — |